COMP <GO>
SNWV vs LLY // EV/EBITDA & P/E VALUATION
SANUWAVE Health Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: SNWV 4
— LLY 8
▲ EV/EBITDA & P/E VALUATION LEADER: SNWV
LAST: $5.27 (0.00%) • MKT CAP: $45.3M
valuation
7.5x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
valuation
36.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SNWV VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SNWV | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.10% | 83.64% | -6.54 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 67.30% | 32.36% | +34.94 | SNWV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 7.5x | 36.4x | -28.92 | SNWV | /valuation <GO> |
| Free Cash Flow Yield | 4.27% | 2.30% | +1.97 | SNWV | /fcf-yield <GO> |
| Operating Margin | 11.20% | 40.21% | -29.01 | LLY | /operating-margins <GO> |
| Net Profit Margin | 26.80% | 31.90% | -5.10 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 36.30% | 45.51% | -9.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 9.29 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.4 | 66.6 | -16.24 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 3.5x | 26.3x | -22.75 | SNWV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $45.3M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SNWV REV | LLY REV | SNWV GROSS % | LLY GROSS % | SNWV FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.1M | $65.18B | 77.1% | 83.0% | $1.9M | $16.81B |
| FY 2024 | $32.3M | $45.04B | 75.9% | 81.3% | $2.0M | $8.82B |
| FY 2023 | $19.3M | $34.12B | — | 79.3% | -$4.5M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SNWV // BETA —
LLY // BETA 0.51